Financial Data and Key Metrics Changes - The company reported total revenue of $16 million for Q4 2025, representing a 4% decline year-over-year, primarily due to lower system sales [18] - Full year 2025 revenue increased by 9% compared to 2024, with recurring revenue growing by 15% [20][21] - The gross margin for Q4 was 43%, slightly up from 42% in Q4 2024, while the full year gross margin was 46%, down from 48% in 2024 [22][23] Business Line Data and Key Metrics Changes - The installed base of ALLY systems grew to approximately 200, with a 48% year-over-year increase, and procedure volume increased by 20% year-over-year [22] - The company achieved a 23.4% procedure share in the U.S. by the end of 2025, up from 14% [10] - The company placed 15 ALLY systems in Q4 2025, contributing to a total of 206,000 procedures globally for the year [22] Market Data and Key Metrics Changes - U.S. ALLY sales increased by one system to 12 in Q4 2025, while international sales dropped significantly from 10 systems in Q4 2024 to just one in Q4 2025 [18][19] - The company noted that the uncertainty surrounding the acquisition negatively impacted international business expansion [13] Company Strategy and Development Direction - The company aims to focus on growing procedure volumes and recurring revenue through additional system placements and increased utilization of existing systems [15] - The strategy includes re-engaging with distributors and stakeholders to regain momentum lost during the acquisition process [14] - The company plans to explore new markets, including Australia and New Zealand, and expand its presence in Europe and Southeast Asia [50][55] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to historical operating performance and emphasized the importance of rebuilding momentum over the next several quarters [9][61] - The company acknowledged the challenges faced during the acquisition process but highlighted the validation of its technology and market position [5][6] - Management expects to see gradual improvements in system sales and recurring revenue as distributors re-engage [20][42] Other Important Information - The company received a $10 million transaction deposit following the termination of the acquisition, which will enhance its cash position [8][17] - The company recorded $17.1 million in total acquisition costs in 2025, with a portion expected to be eliminated due to the termination of the merger [17] Q&A Session Summary Question: Can you elaborate on the distributor commentary and its impact on growth? - Management indicated that while conversations with distributors have been positive, it will take time to regain momentum in international markets due to previous uncertainties [29][32] Question: How should we think about the mix of capital placements versus lease-based placements? - Management noted that revenue recognition differs between U.S. and international sales, with a potential shift towards more lease-based placements in the U.S. [33][36] Question: Can you clarify the expected increase in operating expenses for 2026? - Management confirmed that cash-based operating expenses are expected to increase by 10%, excluding merger-related costs [37][38] Question: What is the outlook for U.S. procedure growth given recent trends? - Management reported that recurring revenue is becoming healthy, with expectations for continued growth in procedure volumes driven by the installed base [41][42] Question: Are there new market opportunities outside the U.S.? - Management expressed interest in exploring markets like Australia and New Zealand, as well as expanding in Europe and Southeast Asia [50][55]

Financial Data and Key Metrics Changes - In 2025, the company achieved a 9% revenue growth compared to 2024, with total revenue of $16 million in Q4, representing a 4% decline year-over-year primarily due to lower system sales [9][18] - Recurring revenue increased by 15% over 2024, reaching $46.3 million for the full year, with Q4 recurring revenue growing 17% to $12.7 million [20][21] - Gross margin for Q4 was 43%, slightly up from 42% in Q4 2024, while the full year gross margin was 46%, down from 48% in 2024 due to inflationary costs and tariffs [22][23] Business Line Data and Key Metrics Changes - The installed base of ALLY systems grew by nearly 50% compared to year-end 2024, reaching approximately 200 systems, with procedure volume increasing by over 20% year-over-year for both Q4 and the full year [8][21] - The company placed 15 ALLY systems in Q4, contributing to a total of 206,000 procedures globally for the year, with a significant increase in market share from 14% to 23.4% in the U.S. [10][21] Market Data and Key Metrics Changes - The company faced challenges in international markets due to uncertainty surrounding the acquisition, leading to only one ALLY system sale outside the U.S. in Q4 2025, compared to 10 in Q4 2024 [18][19] - The company anticipates a gradual return to significant system growth in international markets as distributors re-engage following the termination of the merger [14][19] Company Strategy and Development Direction - The company aims to focus on growing procedure volumes and recurring revenue through additional system placements and increased utilization of existing systems [15][24] - The strategy includes maintaining cost discipline and enhancing cash flow, particularly as international sales ramp up [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to historical operating performance, with expectations for gradual growth in 2026 following a challenging 2025 [9][24] - The termination of the merger is viewed as an opportunity to refocus and capitalize on market opportunities, with management confident in the company's ability to drive long-term success [59][60] Other Important Information - The company received a $10 million transaction deposit following the termination of the merger, which will enhance its cash position [8][17] - The company recorded $17.1 million in total acquisition costs in 2025, with a portion of these costs expected to be eliminated due to the merger's termination [17][23] Q&A Session Summary Question: Distributor commentary and growth re-acceleration - Management acknowledged positive conversations with distributors but cautioned that it may take several quarters to regain momentum in international markets [28][30] Question: U.S. procedure growth and recurring revenue - Management indicated that U.S. procedure growth remains strong, with expectations for continued performance from the installed base of systems [39][40] Question: Operating expenses and future projections - Management confirmed a 10% increase in cash-based operating expenses for 2026, with expectations for further increases in 2027 as operations stabilize [35][45] Question: Opportunities in international markets - Management highlighted potential growth in markets like Australia and New Zealand, as well as a return to activity in Southeast Asia and Europe [46][48]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $16 million, representing a 4% decline year-over-year primarily due to lower system sales [19] - Full year 2025 revenue increased by 9% compared to 2024, with recurring revenue growing by 15% [21][22] - Gross margin for Q4 2025 was $6.9 million, representing a gross margin percentage of 43%, compared to 42% in Q4 2024 [23] - Full year gross margin was 46%, down from 48% in 2024, attributed to inflationary cost increases and tariffs [24] Business Line Data and Key Metrics Changes - The installed base of ALLY systems grew to approximately 200, up 48% year-over-year, with procedure volume increasing by 20% year-over-year in Q4 2025 [23] - Procedure volumes for the full year 2025 surpassed 206,000 globally, reflecting a 22% growth [23] - U.S. ALLY sales in Q4 2025 included 12 systems, an increase of 1 system from Q4 2024, while international sales dropped significantly [19][20] Market Data and Key Metrics Changes - Market share in the U.S. increased from 14% to 23.4% over 3.5 years, with significant gains from replacing first-generation lasers [10] - The company noted that nearly 50% of new systems in Q4 2025 were sold to femto-naive surgeons, expanding the market for laser-assisted cataract surgery [11] Company Strategy and Development Direction - The company aims to focus on growing procedure volumes and recurring revenue through additional system placements and increased utilization of existing systems [16] - Plans to re-engage with distributors and key stakeholders to regain momentum in international markets following the termination of the acquisition [15] - The company is exploring new market opportunities, including Australia and New Zealand, and intends to expand its presence in Europe and Southeast Asia [52][56] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to historical operating performance and emphasized the importance of rebuilding momentum over the next several quarters [9][26] - The termination of the merger was viewed as an opportunity to focus on independent growth and capitalize on market opportunities [66] - Management acknowledged the challenges faced during the acquisition process but highlighted the potential for long-term success and value creation [15][66] Other Important Information - The company received a $10 million transaction deposit following the termination of the merger, which will enhance cash flow [8][18] - Adjusted EBITDA for Q4 2025 was positive at $595,000, indicating operational cash flow positivity despite the challenges faced [25] Q&A Session Summary Question: Distributor commentary and growth re-acceleration - Management noted that while initial conversations with distributors have been positive, it will take several quarters to regain momentum in international markets due to previous uncertainties [30][33] Question: U.S. procedure growth and recurring revenue - Management indicated that U.S. procedure growth remains strong, with expectations for continued growth in recurring revenue as the installed base of systems increases [41][43] Question: Operating expenses and future projections - Management confirmed that cash-based operating expenses are expected to increase by no more than 10% in 2026, primarily focused on commercial activities [37][49]

Company Overview - Alcon Inc. has launched the Clareon PanOptix Pro intraocular lens (IOL) for cataract patients in the U.S., utilizing ENLIGHTEN NXT Optical technology for superior light utilization and minimal light scatter [1][5] - The company has a market capitalization of $45.76 billion and has consistently beaten earnings expectations over the last four quarters, with an average surprise of 5.92% [4] Product Details - The Clareon PanOptix Pro is designed to enhance near and intermediate vision, offering a range of powers from +6.0 to +34.0 diopters, and includes features for blue light and ultraviolet filtering [6] - The lens is expected to recover 50% of light lost to scatter, improving visual clarity post-cataract surgery [5] Market Position and Trends - Alcon's Surgical segment is benefiting from a diverse product portfolio and strong demand for presbyopia-correcting IOLs, maintaining a leading market share [3] - Following the product launch, Alcon's stock experienced a slight decline of 0.1%, but has seen a 10.5% increase over the past year, outperforming the industry [2] Industry Prospects - The global intraocular lens market was valued at $4.0 billion in 2022 and is projected to grow at a compound annual growth rate of 6.3%, reaching $6.0 billion by 2029, driven by an increase in cataract surgeries and an aging population [10] Recent Developments - Alcon's Clareon Vivity IOL received CE Mark approval, and the company has entered an agreement to acquire LENSAR, enhancing its capabilities in advanced laser solutions for cataract treatment [11][12] - The PanOptix Pro will be available in select U.S. practices, with broader availability expected in May and additional markets rolling out by late 2025 [7][8]

Core Insights - Alcon's Clareon Vivity intraocular lens (IOL) has received CE Mark approval, set for commercial rollout in Europe by early Q2 2025, enhancing visual options for patients [1][2] - The lens addresses presbyopia, providing extended depth of focus (EDOF) for clearer vision at multiple distances, unlike traditional monofocal lenses [5][8] - Alcon's market capitalization stands at $44.67 billion, with a recent earnings surprise of 2.9% [4] Company Developments - Alcon's Surgical segment benefits from a diverse portfolio and innovation, particularly in cataract consumables, with positive market sentiment expected following recent agreements [4] - The acquisition of LENSAR, a leader in advanced laser solutions for cataract treatment, strengthens Alcon's portfolio in femtosecond laser-assisted cataract surgery [10] Stock Performance - Following the news, Alcon's shares increased nearly 2%, closing at $92.35, although the stock has seen a 6.5% decline over the past six months compared to the industry's 8.4% decline [3] - The S&P 500 experienced a 0.6% decline in the same timeframe [3]